Loud Messengers — P Values and Effect Size
Part of the application process for medical school admissions includes an interview with several faculty at the institution. While visiting one medical school that was considering me as a candidate, I was interviewed by a basic scientist— a neurophysiologist. During our conversation, the topic eventually turned to research. The interviewer finally commented that he was lamenting over a failed manuscript submission. Indulging my request for additional information, he related that his manuscript had been rejected by a prestigious journal, apparently for lack of statistical significance. Since I had some exposure to p values, we discussed their meaning and nonmeaning, jointly groping toward some inner truth, and finally realized together that “statistical significance” does not go hand in hand with clinical significance. We together broke some of the bonds with which p values had tied us so tightly. The purpose of this chapter is to break some more.
KeywordsHigh Blood Pressure Attributable Risk Primary Pulmonary Hypertension Expert Testimony Hazardous Drinking
Unable to display preview. Download preview PDF.
- 1.Noremberg, D., LRC, (1996) Letter to the Editor. JAMA 252: 2545.Google Scholar
- 3.Ouellet, B.L., Romeder, J.M. and Lance, J.M., (1979b) “Premature mortality attributable to smoking and hazardous drinking in Canada,” Am. J. Epidemiology 109: 451–463.Google Scholar
- 6.Times Newspaper Ltd., The Sunday Times of London, (1979) “Suffer the Children: The Story of Thalidomide.Google Scholar
- 7.Lenz, W., (1962) “Thalidomide and Congenital Abnormalities,” (Letter to the Editor) Lancet 1:45.Google Scholar
- 8.Clark, C., (1997) Radium Girls: Women and Industrial Health Reform, 1910–1935, University of North Carolina Press, Chapel Hill, NC.Google Scholar
- 9.Sacks, F.M., Pfeffer, M.A., and Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M.O., Wun, C.C., Davis, B.R., Braunwald, E. for the Cholesterol and recurrent Events Trial Investigators, (1996) “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels,” N Engl J Med 335: 1001–1009.PubMedCrossRefGoogle Scholar